Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCY: Olaparib in HER2-ve Metastatic Breast Cancer
NCT03286842Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of olaparib in breast cancer, sponsored by AstraZeneca. Primary endpoint: Progression-free Survival up to 3 years. Started Jan 2018; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03286842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286842.